Anti-CD154 antibody having improved binding, functional and safety characteristics
US10874738B2 · kind B2 · utility
1Cited by
3References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 13, 2016 |
| Grant date | Dec 29, 2020 |
| Priority date | — |
| Expiry date | Apr 24, 2037 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Improved anti-CD154 antibodies are provided herein which have improved therapeutic potency, in vivo half-life and ablated FcR binding and/or complement binding/activation. The use of these antibodies for inducing tolerance and treating immune diseases including autoimmunity, inflammation, transplant recipients, fibrosis and allergic disorders is disclosed herein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.